Member Info for belgrano

Going to go one further here as well. As a "slight discount will be offered to members", I'll wager anyone that we are also going to see "free advertising with the society endorsing the product with member discount" as soon as its available, instead of signing up to express an interest as currently. This is what these forums have been made for and members are dreaming of.
Cant say anymore than that on a public forum at the moment, unless by private coms.

Working with the USA national psoriasis association. 2:20 on for a couple of mins.
https://www.proactiveinvestors.co.uk/companies/news/224009/skinbiotherapeutics-continues-working-on-its-partnerships-224009.html

Hi Train Tracks,
Where you been for the last 6 months LOl. Stuart has very close ties with the USA psoriasis associations, and they asked SBTX to prioritise our product for their members. Stuart has even confirmed that members will get a slight discount. They are co-operating together I've seen him say it. Yes you are correct its not just a captive audience, but a captive audience of the suffering and needy, thats why I 've been saying we are going to be well over subscribed, which is the defining difference of our product and the ones from our parent company. Its also why tyndall are trying to grab as much free float as possible, and why I've been gorging myself silly on this stock.

Hi rebarn, I dont want to share actual material thats been carefully researched and reproduced by a well known poster here whom many like myself subscribe too. Hope you understand, but with research you will also find it. Just trying to walk the tightrope, and pls sometimes take things on trust.
Indeed this only took a few mins.
https://www.cosmeticsdesign-europe.com/Article/2021/09/02/SkinBioTherapeutics-AxisBiotix-probiotic-powder-for-psoriasis-holds-wider-promise-says-CEO

The critical point for SBTX is actual sales uptake this year. Quite frankly its the difference between being a 10 bagger and a stock halfing in value.
Also seeing below is further proof that a well planned marketing strategy using the mighty USA psoriasis forums is already agreed and underway. Indeed they have "been very vocal" in getting Stuart to prioritise this treatment development to aid their huge 6M suffering members.
We are just seeing the start of this campaign, and having participated on those forums myself, and now knowing the pricepoint for product is right I'm convinced the company will initially not be able to produce enough product to satisfy demand. Know many thousands of sufferers have been registering an interest only in subscribing, and that does not means certain numbers in any way , but proves there is going to be a really huge demand for this product.

Short post below copied from ADVFN and was written by respected poster Toyin.

the US psoriasis association has been running adverts for AxisBiotix on their website, referring to sbtx as “partners.”

Clearly some equally big or the same players are topping up this pm as well. This isn't small pi's.

Hi Harris,
This is my uptake and it differs from the others posted.
Traders will always seek profit from any margin and any slight news vacuum presents such an opportunity. It does not have to be bad news in any way, just an opportunity to offload and perhaps buy back cheaper. It was clear that with sales starting 4th quarter we did have some weeks to wait until it happened and in that time unlikely to be news of positive cash flow, coupled with aim drift where there always some investors selling to make other lifestyle choices it was seen as an better than evens opportunity for some pros.

yep looks like those selling down the stock to buy back cheaper have finally started to make some headway. Seems that it's been much more of a struggle as compared when they did it on OPTI a while ago. Clearly going against a pretty strong headwind to do so as well going by the last RNS.
Well I'm holding strong here and just checking for any dry powder. In previous cases there we saw pretty vigorous bounce backs as they rebought and tried to trouser some margins. I dont think we will be waiting long here.

The relatively small group of investors I have on my contact list probably hold approaching that quantity of stock. Tyndall buy stocks for private wealthy clients and haven't any history of exerting influences on their other holdings. Expect order is at current price so its underpinning price, but not letting it rise. Company has right now no decent earn t income, so wide open to jam tomorrow claims. Such stocks however good, do see shareprice drift as investors often get forced to sell for other lifestyle reasons. What they are doing is quietly mopping up all the free float. I think its a very good thing and we don't know for sure their investment plans.

Great spot milky tea and highly significant. Tindal have bought another 1.5m shares, pretty much taking everything that comes on the open market and a major iceberg buy underpinning the shareprice while they attempt to grow their holding to the required level which a few posers who knew the company said they would like 10percent. Well that's an eye watering 6m more shares so good luck with that one.

I suffer only very mild skin conditions (probably like most people), however I would like to subscribe and take the treatment as it does lead to a lot of other minor issues (like dandruff), clearing up.
However I'm sure we will be very much oversubscribed for product, if just the initial numbers of those "expressing an interest"are correct. That's before the main psoriasis forum advertising starts in earnest, led by the organisers of those forums.
In such an event I'll happily wait longer into next year if required to allow more acute sufferers to receive their product as a more increased priority. I don't know if the company has thought of this, and it makes sense in my books...give it to the most needy first, if limited supply which it sounds like it might be.

It was quite noticeable that the answer to positive responses to other inflammatory and skin conditions seen in the recent study wasn't fully answered, in way of giving actual results.
This is actually fair enough because they know the company would then leave its self wide open to criticism as the sample pool is far to low by far which is correct.
Also some comments made that they believe that the psoriasis treatment currently being supplied could be further tweaked (guess this means strain alteration), for optimum performance against more targeted conditions, and why we are going to see another study or two in the not to distant future.
However that's great for the investor, but pants for the sufferer...fully understand that it might not be 72% efficient against other skin conditions, but as there is no known cure to some, even a 30% chance while we await bacteria specialisations for specific conditions in my book is certainly miles better than nothing.

Hi Rocksteady,
Sorry to hear you are a sufferer for this condition which can cause inflammation of the joints with arthritis with no known cure.
Going out a bit on a limb here, but I did hear that arthritis, was one of the conditions that a very small minority on the study saw some relief from, but the target was mainly psoriasis, so not enough people to be able to give direct feed back on as a nailed on given.
Certainly worth a separate e-mail to the company to see if there is any information they would share with you (understanding this is new technology with a minute sample pool of people so far).
Wishing you the best of luck with this painful condition.

Does appear that the re evaluation of OPTI is currently underway with increasing product sales. This is great news for the many long term holders here. Price has been rising slowly but steadily for quite a while with the initial rises being sold into.
However those sales are now completed, and price is responding by ticking up slow but sure.

Cutting edge technology which is highly likely to evolve into a full range of products for treatment for several skin conditions. Each is in itself a huge market.
Good thing is its not being marketed in the distant future but 4th quarter this year, and now its been fully confirmed that Stuart has been working closely with the big USA psoriasis associations (indeed they have managed to persuade him to prioritise this development for their 6M members), as they also rightly are doing the best thing for their millions of sufferers.
Know now that initial product will probably be well oversubscribed, as their many millions of members are actively hunting for any treatment that works.....This is a fact as I've spent a fair amount of time on those forums myself, and see that suffering and heartfelt true stories. I'm really pleased to strongly support a company that's going to bring relief to indeed many hundreds of thousands of people in the next two years.
This is just a few weeks away, and only the first product. It will sell like hot cakes I'm convinced, and I'll also be buying product.

the application on this server wasnt uploading. now it is.

you are right notrac, one thing I did notice, that when new stock tips were announced I used to see an increased level of trading just previously to tips going out to subscribers. Think this ties up with your comments about jockeys and bets. Used to subscribe to "red hot profits" years ago, and when it was paper publications posted to me the same thing used to happen there as well. might have been the printers but clear signs of leakage. Mind you in fairness very few actual shares you never see some small signs of increased activity in.

well I pop in from time to time, guess i'm an investor from the "old days", I remember when "first oil" was struck.
Never managed to bag one of the paperweights as I didn't go to the presentation when they were given out by Todd.
Lot of water under the bridge now.

Believe a lot of things are happening right now, with Winclove gearing up for production and Croda about to churn out 20Tons of the lysate for skin care.
Stuart has gone a bit quiet on the so called "beauty parade", not sure if this is actually on, know if was discussed previously but believe there is just so much going on they are going to leave Croda and sederma to it as it is as Stuart describes it "passive revenue" and concentrate a bit more on the lysate for wound care and closures also infection protection which is another area again involving other specialist companies.
Also as subscriptions develope and "passive revenue" floods in...yep that's a beauty, its already been pointed out by the CEO that "Big pharma do have their eyes on us", for things developing in the longer time period.